Product Details
Fraxiparine
Nadroparin Calcium9500 IU/mL
Solution for Injection
0.6-mL Prefilled Syringe Pack
DIN/PIN/NPN
09853952
Manufacturer
Aspen Pharma Trading Limited
Formulary Listing Date
1999-04-15
Unit Price
9.0580
Amount MOH Pays
9.0580
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
Interchangeable Products
NOLU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| 186 | 1 year | For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; |
| 187 | 1 year | For DVT in pregnant or lactating females; |
| 188 | 1 year | For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; |
| 189 | 1 year | For DVT in patients who have failed treatment with warfarin. |
Requirements
NA
EAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Anticoagulants | Nadroparin
NOTE: Enoxaparin biosimilars are general benefits on the Ontario drug benefit formulary and do not require EAP approval. Other Low Molecular Weight Heparins (LMWHs) (e.g. dalteparin, tinzaparin, fraxiparine) are currently listed on the ODB Formulary as Limited Use (LU) benefits for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in certain patient groups. Please consult the Formulary for further details. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days EAP Drug Request Form: |